Clinical Trials Logo

Hearing Loss, Sensorineural clinical trials

View clinical trials related to Hearing Loss, Sensorineural.

Filter by:

NCT ID: NCT01877317 Completed - Clinical trials for Mild to Moderate Sensorineural Hearing Loss

Study of SelfFit Mobile Medical App for Hearing Loss Diagnostics and Hearing Device Fitting / Fine Tuning

SelfFit
Start date: May 2013
Phase: N/A
Study type: Interventional

The purpose of this clinical study is to validate the comparability of prescription formula fitting of hearing aids based on full diagnostic audiometry and SelfFit interactive fitting of hearing aids based on hearing loss screening (mild to moderate hearing losses) using in-situ audiometry, provided and executed through the mobile medical app.

NCT ID: NCT01867515 Completed - Clinical trials for Hearing Loss, Sensorineural

Spectral Dynamics and Speech Understanding by Hearing Impaired People

Start date: August 2013
Phase: N/A
Study type: Interventional

The purpose of this program of research is to understand the perception of the dynamic spectral properties of speech by hearing-impaired listeners, with the long-term goal of improving speech understanding by these individuals in adverse listening conditions. The proposed research compares the performance of normally-hearing and hearing-impaired listeners on measures of speech understanding in the presence of different types of signal distortion and speech understanding of signals with enhanced spectral dynamics. A computational model based on the amount of potential information available in speech will be used to quantify differences in speech intelligibility due to hearing status and stimulus characteristics.

NCT ID: NCT01749592 Completed - Clinical trials for Sensorineural Hearing Loss (Disorder)

Single-sided Deafness and Cochlear Implants

Start date: December 2012
Phase: N/A
Study type: Interventional

- As the left and right hemisphere are specialized for different auditory tasks, the proposed study aims at demonstrating different consequences of right or left-sided deafness for the affected individual. - Furthermore, the question should be answered if auditory deficits and plastic changes can be partially reversed by cochlear implantation of the deaf ear. - Multicenter, prospective, open, non-randomized clinical trial with 5 patients with right-sided and 5 patients with left-sided sensineural deafness. - Pre-operative: Audiometry, Sound Localization Audiometry, PET, EEG/MEG - Comparison of pre-operative investigations with 10 healthy subjects (age and gender matched control group) - Cochlea implantation - Follow-up Visits at 3, 6, 9 and 12 month post-operative: Audiometry, Sound Localization Audiometry, PET, EEG, Questionnaires - Trial with medical device

NCT ID: NCT01671176 Completed - Clinical trials for Conductive Hearing Loss

Wide Diameter Bone Anchored Implant Study

Start date: May 2012
Phase: N/A
Study type: Interventional

To assess implant stability, implant loss, adverse skin reactions, and Quality of Life Benefit following implantation of the Ponto 4.5mm Wide Diameter implant. Secondary: to determine the feasibility of fitting the sound processor 3 weeks after surgical implantation, and to investigate if the type of skin reactions following implantation could be related to the demographic data of subjects and the type of surgical technique used

NCT ID: NCT01621256 Completed - Hearing Loss Clinical Trials

Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss

Start date: May 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether ancrod is effective and safe in the treatment of sudden sensorineural hearing loss (SSHL).

NCT ID: NCT01532713 Completed - Clinical trials for SSNHL(Sudden Sensory Neural Hearing Loss)

The Effect of Oxygen Administration on Regional Cerebral Oxygen Saturation (rSO2) in the Non-block Side After Stellate Ganglion Block

Start date: January 2012
Phase: N/A
Study type: Interventional

Stellate ganglion block (SGB) is known to increase blood flow to the innervation area of the stellate ganglion. Near infrared spectroscopy reflects changes of blood volume and allows continuous, non-invasive, and bedside monitoring of regional cerebral oxygen saturation (rSO2). Previous studies have shown the increment of the rSO2 on the block side from the baseline and the decrement of the rSO2 on the non-block side after SGB. Patients with cerebral vascular disease undergoing SGB might be at risk a decrease in cerebral blood flow in the non-block side. The investigators researched the effect of oxygen administration on rSO2 in the non-block side using a near infrared spectroscopy after SGB. 5 L/min oxygen was supplied via nasal cannula from 15 minutes after SGB. The rSO2 in the non-block side were measured before SGB and 5, 10, 15, 20, 25 and 30 minutes after SGB. The present study suggests that oxygen administration can increase the rSO2 of non-block side. In conclusion, it is our belief that oxygen supplement is helpful to the patient with cerebral vascular disease during SGB.

NCT ID: NCT01518920 Completed - Clinical trials for Hearing Loss, Sensorineural

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

Start date: December 2011
Phase: Phase 1
Study type: Interventional

The objective of this study is to examine the safety, tolerability, and effects on hearing thresholds of two single doses of PF-04958242 and placebo in subjects with age-related hearing loss.

NCT ID: NCT01509287 Completed - Clinical trials for Donnai-Barrow Syndrome

Metabolic Screening in Patients With Donnai-Barrow Syndrome

Start date: March 2010
Phase:
Study type: Observational

This study focuses on the genetics and metabolism of Donnai-Barrow Syndrome (DBS).

NCT ID: NCT01434446 Completed - Clinical trials for Sensorineural Hearing Loss

The Effect of Sound Stimulation on Hearing Ability

Start date: September 2011
Phase: N/A
Study type: Interventional

In the late 1990s, researchers discovered that acoustic stimuli slow progressive sensorineural hearing loss and exposure to a moderately augmented acoustic environment can delay the loss of auditory function. In addition, prolonged exposure to an augmented acoustic environment could improve age-related auditory changes. These ameliorative effects were shown in several types of mouse strains, as long as the acoustic environment was provided prior to the occurrence of severe hearing loss. In addition to delaying progressive hearing loss, acoustic stimuli could also protect hearing ability against damage by traumatic noise. In particular, a method called forward sound conditioning (i.e., prior exposure to moderate levels of sound) has been shown to reduce noise-induced hearing impairment in a number of mammalian species, including humans. Interestingly, recent report has suggested that low-level sound conditioning also reduces free radical-induced damage to hair cells, increases antioxidant enzyme activity, and reduces Cox-2 expression in cochlea, and can enhance cochlear sensitivity. Specifically, increased cochlear sensitivity was observed when distortion product otoacoustic emissions (DPOAEs) and compound action potentials (CAPs) were measured. In addition to forward sound conditioning, backward sound conditioning (i.e., the use of acoustic stimuli after exposure to a traumatic noise) has been shown to protect hearing ability against acoustic trauma and to prevent the cortical map reorganization induced by traumatic noise. In this study, the investigators examine the effect of sound stimulation on hearing ability in human subjects.

NCT ID: NCT01267994 Completed - Clinical trials for Sensorineural Hearing Loss

A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease

Start date: June 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if Anakinra (an interleukin-1 receptor antagonist) can improve hearing thresholds in those patients with Autoimmune Inner Ear Disease (AIED) that did not respond to oral steroid therapy for a sudden decline in hearing. The patients to be enrolled will have recently completed a course of oral steroids and demonstrated no change in their audiometric thresholds following corticosteroid therapy.